Search

  1. About ProQR Therapeutics

    Page

    An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.

    In front of the entrance of the ProQR office

  2. ProQR founding story

    Page

    When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.

    Daniel de Boer, CEO of ProQR Therapeutics

  4. ProQR Analyst Event

    Webcast

    During this webcast ProQR leadership will highlight key advancements from its clinical-stage pipeline and Axiomer® RNA editing platform.

  5. ProQR Therapeutics Virtual R&D Event 2023

    Webcast

    On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.

  7. ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients

    Webcast

    … ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients ProQR presents Positive Top-Line Results from the Phase 1/2 … link . do 10-10-2019 - 08:00 - do 10-10-2019 - 09:00 ProQR presents Positive Top-Line Results from the Phase 1/2 …

  8. Careers

    Page

    At our offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over 30 nationalities, are passionate and driven to change the lives of patients and their loved ones.

    ProQRians in a meeting

  9. Partnerships

    Page

    ProQR has collaborations with important names in the industry including Eli Lilly and Company. Read more about our partnerships.

    ProQR office entrace doors

  10. Privacy

    Page

    This privacy statement informs our website visitors on what, for what purposes and how we process personal data.